logo
Plus   Neg
Share
Email

Genentech Reports Positive Topline Data From Xolair Phase III Studies

Genentech, a member of the Roche Group (RHHBY), said Omalizumab has met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 phase III trials for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids. Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in both studies. Xolair was well tolerated and the safety profile was consistent with the previous trials.

In the US., Novartis and Genentech, Inc. jointly develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records its sales. The companies plan to discuss the results with the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Salesforce.com Inc. (CRM) slipped nearly 3% in after-hours trading Tuesday. The cloud-based enterprise software marker reported a fourth-quarter profit that trumped Wall Street estimates as did its revenues. However, the company announced that its co-Chief Executive Keith Block is stepping... Home Depot Inc. (HD) on Tuesday reported 5.8 percent increase in fourth-quarter profit, while Macy's Inc. (M) fourth-quarter profit fell 54.1 percent. However, the results of the companies beat analysts' estimates. The retailers have reaffirmed their annual outlook. Healthcare insurer Aetna, a subsidiary of CVS Health Corp., announced the launch of Aetna Whole Health in Atlanta, providing fully insured and self-insured health care network options for employers. Aetna said through the program, it will offer the health care network options to its Health Maintenance Organization and Exclusive Product Organization product portfolios.
Follow RTT
>